Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype.
Ambroise MarçaisLudovic LhermitteMaria ArtesiCécile LaurentKeith DurkinVincent HahautNicolas RosewickFelipe SuarezDavid SibonMorgane CheminantVeronique Avettand-FenoelJulie BruneauMichel GeorgesClaudine PiqueAnne Van den BroekeVahid AsnafiOlivier HerminePublished in: Leukemia (2020)
Adult T-cell leukemia/lymphoma (ATL) carries a poor prognosis even in indolent subtypes. We performed targeted deep sequencing combined with mapping of HTLV-1 proviral integration sites of 61 ATL patients of African and Caribbean origin. This revealed mutations mainly affecting TCR/NF-kB (74%), T-cell trafficking (46%), immune escape (29%), and cell cycle (26%) related pathways, consistent with the genomic landscape previously reported in a large Japanese cohort. To examine the evolution of mutational signatures upon disease progression while tracking the viral integration architecture of the malignant clone, we carried out a longitudinal study of patients who either relapsed or progressed from an indolent to an aggressive subtype. Serial analysis of relapsing patients identified several patterns of clonal evolution. In progressing patients, the longitudinal study revealed NF-kB/NFAT mutations at progression that were present at a subclonal level at diagnosis (allelic frequency < 5%). Moreover, the presence in indolent subtypes of mutations affecting the TCR/NF-kB pathway, whether clonal or subclonal, was associated with significantly shorter time to progression and overall survival. Our observations reveal the clonal dynamics of ATL mutational signatures at relapse and during progression. Our study defines a new subgroup of indolent ATLs characterized by a mutational signature at high risk of transformation.
Keyphrases
- end stage renal disease
- poor prognosis
- chronic kidney disease
- cell cycle
- ejection fraction
- newly diagnosed
- single cell
- oxidative stress
- acute myeloid leukemia
- bone marrow
- randomized controlled trial
- diffuse large b cell lymphoma
- genome wide
- long non coding rna
- lps induced
- sars cov
- rheumatoid arthritis
- acute lymphoblastic leukemia
- dna methylation
- copy number
- nuclear factor
- inflammatory response
- young adults
- high density
- disease activity
- open label
- patient reported
- phase iii